BioSpace News Archive

This newly formed committee of international specialists will advise on the scientific and clinical aspects related to the development of Onxeo’s current and future programs

Noema Pharma AG, a Swiss clinical-stage company targeting orphan neurological disorders, announces it will attend several investor conferences during June and July.

NH TherAguix, a clinical stage company developing innovative nanomedicines for the treatment of cancer, and the CHU Grenoble Alpes announce the publication of the results of the First-In-Human phase 1 clinical trial on the combination of AGuIX, its candidate drug, with radiotherapy on multiple brain metastases patients,by Verry Camilleet al., in Radiotherapy & Oncology medical journal.

Quotient Limited, a commercial-stage diagnostics company, announced the management team will participate in two upcoming investor conferences.

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, announced that the Company will participate in an upcoming virtual investor conference.

Innovent Biologics, Inc. and AnHeart Therapeutics Co., Ltd. jointly announce an exclusive license agreement for the co-development and commercialization of AnHeart’s lead drug candidate, taletrectinib – a next-generation tyrosine kinase inhibitor designed to effectively target ROS1 and NTRK - in Greater China, including mainland China, Hong Kong, Macau and Taiwan.

Scopus BioPharma Inc. announced that the board of directors has rescheduled the company’s 2021 Annual Meeting of Stockholders, which will be held on October 8, 2021.